Patients with a rare disease are asking the Food and Drug Administration a question the agency rarely hears: Is that really your final answer?
A group for people with familial chylomicronemia syndrome (FCS), a genetic condition that causes fat to build up in a person’s blood, is circulating a petition that begs the FDA to reconsider its decision to reject the one experimental treatment for FCS, Akcea’s volanesorsen. As of Monday, the petition had more than 8,000 signatures.
About the Author Reprints
